FNArena Windows

Introduction to FNArena Windows

FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.

Latest Stories

RESEARCH: Interview With CEO Anatara Lifesciences

Stuart Roberts of Pitt Street Research talks to Steve Lydeamore, CEO of Anatara Lifesciences.

Apr 17 2019

FNArena’s Treasure Chest reports on money making ideas from stockbrokers and other experts. After a long period with a negative or neutral position on Mayne Pharma, Wilsons has decided now is the time to buy.

Apr 16 2019

1AD $0.21


$0.40 $0.21



CSL $190.51


$232.69 $159.05 33.1



FTT $0.00 0.00% $0.09 $0.00


MYX $0.66 0.00% $1.43 $0.63 19.9



PAR $1.61


$2.20 $0.00



SPL $1.34


$1.66 $0.87



TPE $1.36


$1.64 $0.90 45.3



Previous Stories
RESEARCH: Anatara Lifesciences’ Zoetis Deal A Company Maker

Mar 15 2019

Pitt Street Research has initiated coverage of Anatara Lifesciences with a bullish view on the recent licensing agreement with Zoetis.

RESEARCH: Neuren Keeps Rest-of-World Rights For Trofinetide

Mar 07 2019

Pitt Street Research sees a case for re-rating as Neuren keeps Rest-of-World rights for Trofinetide.

RESEARCH: New Standard in Pain Assessment

Dec 12 2018

Pitt Street Research has initiated coverage of PainChek.

CSL Expands Therapy Pipeline

Dec 06 2018

Revenue growth in core plasma products is still expected as CSL embarks on new classes of therapy in its R&D pipeline.

RESEARCH: Misunderstood Neurology Drug Developer

Dec 06 2018

Pitt Street Research has initiated coverage on Neuren Pharmaceuticals.

Robust Outlook For CSL

Aug 16 2018

CSL sustained strong growth in multiple divisions in FY18 and is expected to realise benefits from an increased number of plasma collection centres in FY19.

CSL Risk Still To The Upside

Jun 14 2018

The Chartist reports CSL must at some point consolidate but for now a push through $200 is looking likely.

Margin Outlook Grows For Key CSL Products

May 21 2018

CSL is benefiting as new products replace older lines and new specialty treatments come on board, upgrading guidance and widening the margin outlook as costs are lowered.

Orthocell: Next Big Thing In Tissue Engineering?

Apr 06 2018

Regenerative medicine pioneer Orthocell closes in on market payday.

Is CSL’s Outlook Too Conservative?

Feb 15 2018

Brokers appear confident CSL could beat guidance in FY18, thanks to a maiden profit from its flu vaccine, Seqirus. The core business is also expected to be strong.